Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: Comparison between oral and transdermal administration of estrogen

American Journal of Medicine

Volumn 113, Issue 4, 2002, Pages 331-334

  Modena, Maria G ^a   Bursi, Francesca ^a   Fantini, Giuseppe ^a   Cagnacci, Angelo ^a   Carbonieri, Anna ^a   Fortuna, Alessandra ^a   Rossi, Rosario ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ESTROGEN ACTIVITY; FEMALE; HEART RATE; HORMONE SUBSTITUTION; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANK SUM TEST; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; WOMEN'S HEALTH;

EID: 0036702355     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01209-3     Document Type: Article

References (22)

1. Ridker P.M., Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Invest Med. 46:1988;391-395.
2. Ridker P.M., Cushman M., Stampher M.J., et al. Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
3. Ridker P.M., Buring J.E., Shih J., et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 98:1998;731-733.
4. Tracy R.P., Lemaitre R.N., Psaty B.M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly results from the Cardiovascular Health Study and the Rural Health Promotion Project . Arterioscler Thromb Vasc Biol. 17:1997;1121-1127.
5. MRFIT Research Group, Kuller L.H., Tracy R.P., Shaten J., et al. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 144:1996;537-547.
6. Haverkate F., Thompson S.G., Pyke S.D.M., et al. for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 349:1997;462-466.
7. Ridker P.M., Rifai N., Pfeffer M.A., et al. for the Cholesterol And Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:1998;839-844.
8. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 331:1994;417-424.
9. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 97:1998;2007-2011.
10. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843.
11. Ridker P.M., Rifai N., Pfeffer M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol And Recurrent Events (CARE) Investigators. Circulation. 100:1999;230-235.
12. Ridker P.M., Rifai N., Clearfield M., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344:2001;2016-2018.
13. Cushman M., Legault C., Barrett-Connor E., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study . Circulation. 100:1999;717-722.
14. Ridker P.M., Hennekens C.H., Rifai N., et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 100:1999;713-716.
15. Cushman M., Meilahn E.N., Psaty B.M., et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol. 19:1999;893-899.
16. Van Baal W.M., Kenemans P., Van der Mooren M.J., et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost. 81:1999;925-928.
17. Sattar N., Perera M., Small M., Lumsden M.A. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet. 354:1999;487-488.
18. Steingold K.A., Matt D.W., DeZeigler D., et al. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J Clin Endocrinol Metab. 73:1991;275-280.
19. Ferns G.A.A. C-reactive protein a central player in atherogenesis or an epifenomenon? Clin Sci. 100:2001;357-358.
20. Libby P., Ridker M.P. Novel inflammatory markers of coronary risk. Theory versus practice. Circulation. 100:1999;1148-1150.
21. Cantanore F.P., Loverro G., Ingrosso A.M., et al. Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin Rheumatol. 14:1995;157-160.
22. Koh K.K., Cardillo C., Bui M.N., et al. Vascular effect of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 99:1999;354-360.